Compare EPAM Systems Inc (EPAM) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EPAM Systems Inc vs Spyre Therapeutics Inc. Common Stock — how do they compare? EPAM Systems Inc trades at $115.12 (market cap $5.96B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Spyre Therapeutics Inc. Common Stock is the larger of the two by market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, EPAM Systems Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold EPAM Systems Inc for 37 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| EPAM | SYRE | |
|---|---|---|
Market Cap | $5.96B | $7.52B |
Volume | 731,369 | 1,441,031 |
Sector | Technology | Health |
52-Week High | $221.40 | $108.92 |
52-Week Low | $76.04 | $22.18 |
Typical Hold Time | 37 Days | 0 Days |
Enterprise Value | $5.32B | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EPAM Systems trades at $114.63, up 1.41% today, with a bullish technical signal and strong fundamental valuation metrics including a P/E of 15.67 and P/S of 1.12. Recent quarterly earnings have consistently beaten expectations, and the company announced a partnership with Wiz to enhance cloud security (PRNewsWire, 2026-08-25).
The outlook is positive with a consensus price target of $119, representing ~4% upside. Key opportunities include AI-native revenue growth exceeding 11% (Seeking Alpha, 2026-09-02), while risks involve slower North American growth and activist pressure for buybacks (Reuters, 2026-08-31).
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About EPAM Systems Inc
EPAM Systems Inc provides software product development and digital platform engineering services to clients located around the world. The company services include Software Product Development, Custom Application Development, Application Testing, Enterprise Application Platforms, Application Maintenance, and Support and Infrastructure Management. The company focuses on innovative and scalable software solutions. The company uses industry standard and custom developed technology, tools, and platforms to deliver results to handle business challenges. The company primarily offers its solutions in the following industries: financial services, travel and consumer, software and hi-tech, life sciences and healthcare. The majority of revenue is generated from North American clients.
Read more on EPAM →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
